JPWO2020139828A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020139828A5 JPWO2020139828A5 JP2021537759A JP2021537759A JPWO2020139828A5 JP WO2020139828 A5 JPWO2020139828 A5 JP WO2020139828A5 JP 2021537759 A JP2021537759 A JP 2021537759A JP 2021537759 A JP2021537759 A JP 2021537759A JP WO2020139828 A5 JPWO2020139828 A5 JP WO2020139828A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administering
- period
- tumor
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 51
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 15
- 230000003442 weekly effect Effects 0.000 claims 15
- 238000012423 maintenance Methods 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 6
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 6
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 5
- 102100033499 Interleukin-34 Human genes 0.000 claims 4
- 101710181549 Interleukin-34 Proteins 0.000 claims 4
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- TVGAHWWPABTBCX-UHFFFAOYSA-N vimseltinib Chemical compound O=C1N(C)C(NC(C)C)=NC=C1C(N=C1C)=CC=C1OC1=CC=NC(C2=CN(C)N=C2)=C1 TVGAHWWPABTBCX-UHFFFAOYSA-N 0.000 claims 2
- -1 (1-methyl-1H-pyrazol-4-yl)pyridin-4-yl Chemical group 0.000 claims 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229950003054 binimetinib Drugs 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000008416 bone turnover Effects 0.000 claims 1
- 210000004900 c-terminal fragment Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229960002271 cobimetinib Drugs 0.000 claims 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 1
- 229960003649 eribulin Drugs 0.000 claims 1
- 210000003722 extracellular fluid Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000008298 histiocytosis Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000004898 n-terminal fragment Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025009594A JP2025066790A (ja) | 2018-12-28 | 2025-01-23 | 癌の治療において使用するためのｃｓｆ１ｒ阻害剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786105P | 2018-12-28 | 2018-12-28 | |
| US62/786,105 | 2018-12-28 | ||
| US201962926341P | 2019-10-25 | 2019-10-25 | |
| US62/926,341 | 2019-10-25 | ||
| US201962933830P | 2019-11-11 | 2019-11-11 | |
| US62/933,830 | 2019-11-11 | ||
| PCT/US2019/068311 WO2020139828A1 (en) | 2018-12-28 | 2019-12-23 | Csf1r inhibitors for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025009594A Division JP2025066790A (ja) | 2018-12-28 | 2025-01-23 | 癌の治療において使用するためのｃｓｆ１ｒ阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516090A JP2022516090A (ja) | 2022-02-24 |
| JPWO2020139828A5 true JPWO2020139828A5 (https=) | 2024-03-12 |
| JP2022516090A5 JP2022516090A5 (https=) | 2024-03-12 |
| JP7626702B2 JP7626702B2 (ja) | 2025-02-04 |
Family
ID=69191281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537759A Active JP7626702B2 (ja) | 2018-12-28 | 2019-12-23 | 癌の治療において使用するためのｃｓｆ１ｒ阻害剤 |
| JP2025009594A Pending JP2025066790A (ja) | 2018-12-28 | 2025-01-23 | 癌の治療において使用するためのｃｓｆ１ｒ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025009594A Pending JP2025066790A (ja) | 2018-12-28 | 2025-01-23 | 癌の治療において使用するためのｃｓｆ１ｒ阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US11103507B2 (https=) |
| EP (3) | EP4647767A3 (https=) |
| JP (2) | JP7626702B2 (https=) |
| KR (1) | KR20210119411A (https=) |
| CN (4) | CN118453608A (https=) |
| AU (3) | AU2019416117B2 (https=) |
| BR (1) | BR112021012812A2 (https=) |
| CA (1) | CA3124112A1 (https=) |
| DK (2) | DK3902547T3 (https=) |
| ES (2) | ES3049362T3 (https=) |
| FI (3) | FI3902547T3 (https=) |
| HR (2) | HRP20231478T1 (https=) |
| HU (2) | HUE073437T2 (https=) |
| IL (2) | IL284199B1 (https=) |
| LT (3) | LT4303583T (https=) |
| MX (2) | MX2021007927A (https=) |
| NO (1) | NO2026009I1 (https=) |
| PL (2) | PL3902547T3 (https=) |
| PT (2) | PT3902547T (https=) |
| RS (2) | RS67303B1 (https=) |
| SG (1) | SG11202105747XA (https=) |
| SI (2) | SI3902547T1 (https=) |
| SM (2) | SMT202500389T1 (https=) |
| TW (2) | TWI873113B (https=) |
| WO (1) | WO2020139828A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| SMT202500389T1 (it) * | 2018-12-28 | 2025-11-10 | Deciphera Pharmaceuticals Llc | Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
| IL325201A (en) | 2019-06-17 | 2026-02-01 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of using them |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| AU2021348477B2 (en) * | 2020-09-23 | 2023-12-21 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Csf1r kinase inhibitor and use thereof |
| MX2023005747A (es) | 2020-11-18 | 2023-07-28 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. |
| CN113880812A (zh) * | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| KR20240113496A (ko) | 2021-12-03 | 2024-07-22 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물 |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| EP4587059A2 (en) * | 2022-09-12 | 2025-07-23 | Ammax Bio, Inc | Treatment of tenosynovial giant cell tumor |
| EP4483866A1 (en) | 2023-06-28 | 2025-01-01 | Makrolife Biotech GmbH | Pharmaceutical compositions for the treatment or prevention of cancer |
| WO2025096349A1 (en) * | 2023-10-29 | 2025-05-08 | Deciphera Pharmaceuticals, Llc | Methods of treating tenosynovial giant cell tumors |
| CN117624132B (zh) * | 2023-11-28 | 2026-04-21 | 上海相辉医药科技有限公司 | 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 |
| US20250206720A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Solid forms of an ulk inhibitor |
| WO2025122952A1 (en) * | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5794047A (en) | 1980-12-01 | 1982-06-11 | Ricoh Co Ltd | Novel disazo compound and preparation of the same |
| KR100874791B1 (ko) | 2001-05-29 | 2008-12-18 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도 |
| EP2258366B1 (en) | 2001-06-22 | 2013-04-03 | Kirin Pharma Kabushiki Kaisha | Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| PE20080359A1 (es) | 2006-04-19 | 2008-06-06 | Novartis Ag | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| KR20100014811A (ko) | 2007-04-20 | 2010-02-11 | 데시페라 파마슈티칼스, 엘엘씨. | 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제 |
| ES2401550T3 (es) | 2008-02-28 | 2013-04-22 | Merck Patent Gmbh | Inhibidores de proteína cinasa y uso de los mismos |
| CN102256493A (zh) | 2008-10-29 | 2011-11-23 | 迪赛孚尔制药有限公司 | 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物 |
| BR112012027743A2 (pt) | 2010-04-29 | 2017-03-14 | Deciphera Pharmaceuticals Llc | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas |
| EP2563773A1 (en) | 2010-04-29 | 2013-03-06 | Deciphera Pharmaceuticals, LLC | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| BR112014012407A2 (pt) | 2011-11-22 | 2017-06-06 | Deciphera Pharmaceuticals Llc | amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas |
| US9187474B2 (en) | 2012-03-07 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US9758258B2 (en) | 2012-11-29 | 2017-09-12 | Sirkorsky Aircraft Corporation | Rotary wing aircraft blade tracking |
| CA2903285C (en) | 2013-03-15 | 2021-05-11 | Deciphera Pharmaceuticals, Llc | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| RU2769607C2 (ru) | 2013-03-15 | 2022-04-04 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность |
| US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2014145004A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9309224B2 (en) | 2013-03-15 | 2016-04-12 | Deciphera Pharmaceuticals, Llc. | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| JP2020510673A (ja) | 2017-03-03 | 2020-04-09 | ヤンセン バイオテツク，インコーポレーテツド | がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法 |
| EP3632906B1 (en) | 2017-05-24 | 2023-12-13 | Abbisko Therapeutics Co., Ltd. | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy |
| EP3632907B1 (en) | 2017-05-24 | 2024-02-28 | Abbisko Therapeutics Co., Ltd. | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof |
| CA3065365C (en) | 2017-05-30 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR |
| CA3075892C (en) | 2017-09-14 | 2024-01-23 | Daiichi Sankyo Company, Limited | Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| SMT202500389T1 (it) * | 2018-12-28 | 2025-11-10 | Deciphera Pharmaceuticals Llc | Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
| TWI912522B (zh) | 2021-05-24 | 2026-01-21 | 大陸商上海和譽生物醫藥科技有限公司 | 一種結晶型csf-1r抑制劑酸式鹽及其製備方法和應用 |
| CN113880812A (zh) | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| CN116283919A (zh) | 2023-03-21 | 2023-06-23 | 上海皓元医药股份有限公司 | Vimseltinib的新晶型及其制备方法 |
-
2019
- 2019-12-23 SM SM20250389T patent/SMT202500389T1/it unknown
- 2019-12-23 RS RS20251011A patent/RS67303B1/sr unknown
- 2019-12-23 ES ES23195809T patent/ES3049362T3/es active Active
- 2019-12-23 MX MX2021007927A patent/MX2021007927A/es unknown
- 2019-12-23 HR HRP20231478TT patent/HRP20231478T1/hr unknown
- 2019-12-23 RS RS20231149A patent/RS64993B1/sr unknown
- 2019-12-23 CN CN202410608814.7A patent/CN118453608A/zh active Pending
- 2019-12-23 CN CN202410608820.2A patent/CN118453609A/zh active Pending
- 2019-12-23 CA CA3124112A patent/CA3124112A1/en active Pending
- 2019-12-23 HU HUE23195809A patent/HUE073437T2/hu unknown
- 2019-12-23 SG SG11202105747XA patent/SG11202105747XA/en unknown
- 2019-12-23 JP JP2021537759A patent/JP7626702B2/ja active Active
- 2019-12-23 HR HRP20251261TT patent/HRP20251261T1/hr unknown
- 2019-12-23 PL PL19842712.2T patent/PL3902547T3/pl unknown
- 2019-12-23 SI SI201930651T patent/SI3902547T1/sl unknown
- 2019-12-23 LT LTEP23195809.1T patent/LT4303583T/lt unknown
- 2019-12-23 CN CN202410608828.9A patent/CN118453610A/zh active Pending
- 2019-12-23 PT PT198427122T patent/PT3902547T/pt unknown
- 2019-12-23 DK DK19842712.2T patent/DK3902547T3/da active
- 2019-12-23 PT PT231958091T patent/PT4303583T/pt unknown
- 2019-12-23 LT LTEPPCT/US2019/068311T patent/LT3902547T/lt unknown
- 2019-12-23 FI FIEP19842712.2T patent/FI3902547T3/fi active
- 2019-12-23 SI SI201930977T patent/SI4303583T1/sl unknown
- 2019-12-23 CN CN201980092790.1A patent/CN113453684B/zh active Active
- 2019-12-23 HU HUE19842712A patent/HUE065492T2/hu unknown
- 2019-12-23 DK DK23195809.1T patent/DK4303583T3/da active
- 2019-12-23 KR KR1020217024011A patent/KR20210119411A/ko not_active Ceased
- 2019-12-23 WO PCT/US2019/068311 patent/WO2020139828A1/en not_active Ceased
- 2019-12-23 US US16/725,282 patent/US11103507B2/en active Active
- 2019-12-23 ES ES19842712T patent/ES2964489T3/es active Active
- 2019-12-23 BR BR112021012812A patent/BR112021012812A2/pt unknown
- 2019-12-23 EP EP25190979.2A patent/EP4647767A3/en active Pending
- 2019-12-23 AU AU2019416117A patent/AU2019416117B2/en active Active
- 2019-12-23 EP EP19842712.2A patent/EP3902547B1/en active Active
- 2019-12-23 SM SM20230468T patent/SMT202300468T1/it unknown
- 2019-12-23 PL PL23195809.1T patent/PL4303583T3/pl unknown
- 2019-12-23 FI FIEP23195809.1T patent/FI4303583T3/fi active
- 2019-12-23 EP EP23195809.1A patent/EP4303583B1/en active Active
- 2019-12-27 TW TW108148219A patent/TWI873113B/zh active
- 2019-12-27 TW TW114101930A patent/TW202541807A/zh unknown
-
2021
- 2021-06-20 IL IL284199A patent/IL284199B1/en unknown
- 2021-06-25 US US17/358,137 patent/US11679110B2/en active Active
- 2021-06-28 MX MX2024002838A patent/MX2024002838A/es unknown
-
2023
- 2023-04-28 US US18/140,942 patent/US12285430B2/en active Active
-
2024
- 2024-07-22 AU AU2024205010A patent/AU2024205010B2/en active Active
-
2025
- 2025-01-23 JP JP2025009594A patent/JP2025066790A/ja active Pending
- 2025-03-14 US US19/079,727 patent/US12485120B2/en active Active
- 2025-10-21 US US19/364,654 patent/US12582655B2/en active Active
- 2025-12-18 IL IL325448A patent/IL325448A/en unknown
-
2026
- 2026-01-30 AU AU2026200677A patent/AU2026200677A1/en active Pending
- 2026-03-03 NO NO2026009C patent/NO2026009I1/no unknown
- 2026-03-03 LT LTPA2026508C patent/LTPA2026508I1/lt unknown
- 2026-03-05 FI FIC20260007C patent/FIC20260007I1/fi unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020139828A5 (https=) | ||
| Hewish et al. | Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine | |
| Chu | An update on the current and emerging targeted agents in metastatic colorectal cancer | |
| EP3389634B1 (en) | Methods for treating cancer | |
| US20230181565A1 (en) | Crenolanib combination therapy | |
| Fenn et al. | Phase 1 study of erlotinib and metformin in metastatic triple-negative breast cancer | |
| Aprile et al. | Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight | |
| EP3389652B1 (en) | Methods for treating cancer | |
| EP3721906A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| Scaringi et al. | Combining molecular targeted agents with radiation therapy for malignant gliomas | |
| KR20190119507A (ko) | 제약학적 복합제제 | |
| US11701356B2 (en) | Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor | |
| Tuccillo et al. | Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor | |
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| Sachdev et al. | Evolution of bevacizumab-based therapy in the management of breast cancer | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| Longo et al. | Integrated therapy of kidney cancer | |
| BR112020026382A2 (pt) | combinações de poziotinibe com um anticorpo anti-her1, her2 ou her4 e métodos de uso das mesmas | |
| Duenas-Gonzalez et al. | Pharmacotherapy options for locally advanced and advanced cervical cancer | |
| JP2005511663A5 (https=) | ||
| KR20230110254A (ko) | Sting 작용제, 관문 저해제, 및 방사선의 투여 | |
| Ademuyiwa et al. | Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| Lee et al. | A Phase 1b/2a study of GC1118 with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with recurrent or metastatic colorectal cancer | |
| JP2021138693A (ja) | がんを処置するための方法 |